Opinion on Biotechnology in Germany

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Shire Pharmaceuticals: transatlantic growth spurt

Published By Datamonitor
11 Dec 2000
CommentWire
CommentWire

Bayer/CuraGen: billion-dollar genomics alliance

Published By Datamonitor
19 Jan 2001
CommentWire
CommentWire

Schering AG: smaller, but maybe more successful

Published By Datamonitor
21 Mar 2001
CommentWire
CommentWire

Celltech: more biotech consolidation

Published By Datamonitor
13 Sep 2001
CommentWire
CommentWire

Infectech/ERBC: licensing deal bodes well for biotech sector

ERBC will fund tests into Infectech's early identification technology for bacterial infections. The German bank, which already has a broad base of technology sector investments, will gain European licensing rights to any resulting products. ERBC's move could spark an upturn in investor interest in the biotechnology sector.

Published By Datamonitor
29 Jan 2002
CommentWire
CommentWire

Anadys: hepatitis C grant should boost research

The German government has awarded US-based biotech company Anadys a grant to identify proteins involved in hepatitis C transmission. Anadys' novel approach to drug development could well result in the development of more effective products, which would enhance the company's position in the anti-infectives field.

Published By Datamonitor
02 Jul 2002
CommentWire
CommentWire

Schering AG: harvesting the benefits

Schering AG's June sale of its Aventis CropScience stake has provided a E1.5 billion cashpile, which the company is investing in its pharma business. Two deals completed in the last week should boost the German firm's profile as an innovative biotech-focused pharma company, driving near-double-figure annual growth for the next five years.

Published By Datamonitor
03 Jul 2002
CommentWire
CommentWire

MorphoSys/Roche: antibody hopes for Alzheimer's

German biotech MorphoSys and its partner Roche have achieved a key milestone in discovering a series of antibodies to treat CNS disorders such as Alzheimer's disease. While there are still serious technical and clinical challenges ahead, this innovative new development is certainly good news for Europe's biotechnology sector.

Published By Datamonitor
10 Jul 2002
Expert View
Expert View

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor
02 Aug 2002
ResearchWire
ResearchWire

Knee arthroplasty: 90% of bearings used in Germany are mobile

Published By Datamonitor
03 Sep 2002

« | 1 | 2 | » »|

No help is available.